Pipeline

NM-IL-12 (Recombinant Human Interleukin-12)

HemaMax™ (NM-IL-12) for Surgical Wound Infections (SWI)

The emergence of multi-drug resistant and atypical pathogens has led to a rise in post-operative complications in the hospital (nosocomial) setting in a range of surgical procedures involving skin incisions. At times, the risk of such complications has reduced therapeutic options for trauma patients and wounded military personnel. NM-IL-12, as an immune stimulant, may work by a different mechanism than traditional antibiotics, and it is hoped that the drug will exhibit broad-spectrum activity against many bacterial, viral, fungal[2], and parasitic pathogens implicated in cutaneous infections by increasing location concentrations of Interferon Gamma[3]. Neumedicines is planning to develop NM-IL-12 for use as a surgical incision infection anti-infective prophylactic agent. Its potential for this application has been documented by the accelerated closure of full-thickness wounds in mice by the mouse-version of IL-12 (called rMuIL-12). The safety of NM-IL-12 is being tested in healthy human volunteers.

If clinical trials show results similar to the effects observed in animal trials, it is hoped that the successful clinical development of NM-IL-12 for the treatment of battle and traumatic wounds could:

  1. reduce morbidity in post-surgical patients, trauma patients, and wounded military personnel;
  2. suppress wound infections that have already occurred, via stimulation of the production of Interferon Gamma; and
  3. accelerate wound healing, as was shown in mice, theorized to have occurred through the induction of localized protective innate immunity and tissue repair mechanisms.

2. Duvic, M, et. al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol. 2006 Nov;55(5):807-13. Epub 2006 Sep 8.
3. Trudeau, C., et. al. A Single Administration of Recombinant Human Interleukin-12 Is Associated With Increased Expression Levels of Interferon-gamma and Signal Transducer and Activator of Transcription in Healthy SubjectsJ Clin Pharmacol 2005;45:649-658

© 2009 Neumedicines Inc. All rights reserved.